CD34 and Miyoshi myopathy: Randomized controlled trials (RCTs) comparing the efficacy of G-CSF alone, chemotherapy + G-CSF, plerixafor + G-CSF and motixafortide + G-CSF to mobilize optimal HSPC numbers (≥6 × 106 CD34+ cells kg–1) in the current era of MM therapy are lacking.